Making IL-6 ELISA Kits More Affordable
We´re excited to offer our customers a significant price drop by 15% on our
human Interleukin-6 ELISA kit (cat. no. BI-IL6)
Quality and fully validated assay with ready to use reagents for affordable and efficient research!
⇒ Contact us or our local representative
Making IL-6 ELISA Kits More Affordable
Take 15% OFF of the human IL-6 ELISA Assay now through end of 2024!
BIOMEDICA´s human Interleukin-6 (IL-6) ELISA Assay is highly sensitive and shows detectable values in serum and in plasma samples.
Features & Benefits
- High Specificity – using characterized epitope-mapped antibodies
- High Sensitivity – detectable values in both serum and plasma
- Superior Quality – validated according to international quality guidelines
- Standardized – use of WHO intern.standards for kit calibration & harmonization
- User-Friendly –ready to use color coded prediluted standards & controls
BIOMEDICA Human IL-6 ELISA kit
- Product code: BI-IL6
- Method: ELISA
- Time to result: 4.5 hours
- Sample types: human serum, plasma (EDTA, citrate, heparin), cell culture supernatants, urine
- Sample volume: 100 µl/well
- Sensitivity LOD: 0.28 pg/ml (measurable concentrations in serum AND plasma samples!)
- Standard curve range: 0 – 200 pg/ml (0 / 3.12 / 6.25 / 12.5 / 25/ 50 / 100 / 200)
- Specificity: Endogenous and recombinant human IL-6
- Protokol booklet
- Validation data file
About Interleukin-6
Interleukin-6 (IL-6) is a multifunctional cytokine that plays an important role in the body´s response to tissue injury or infection. Il-6 is produced by various cells, including T-cells, B-cells, macrophages, as well as vascular endothelial cells, mast cells, and dentritic cells (1). Il-6 secretion is stimulated during inflammatory response and travels through the bloodstream to the liver, where it induces the production of acute phase reactants such as C-reactive protein and others (1).
Clinical significance of Interleukin-6
-Inflammatory diseases: elevated IL-6 levels are detected in various inflammatory conditions such as rheumatoid arthritis (2), systemic lupus erythematosus (3) , and inflammatory bowel disease (4). Therapies targeting Il-6 have been already approved (5).
-Cancer: Il-6 is abundantly present in the tumor microenvironment of various tumours. It promotes tumnorigenesis, invasiveness, and metastases in cancer (6). New perspectives in cancer immunotherapy targeting IL-6 are discussed (7).
-Metabolic diseases: Dysregulated IL-6 activity is associated with pathologies involving chronic inflammation and autoimmunity including metabolic diseases like obesity, metabolic syndrome or type-2 diabetes (8).
Literature
- Interleukin 6: at the interface of human health and disease. Grebenciucova E et al., Front Immunol. 2023; 28;14:1255533. PMID: 37841263.
- Interleukin-6 in Rheumatoid Arthritis. Pandolfi F et al., Int J Mol Sci. 2020 ; 23;21(15):5238. PMID: 32718086; PMCID:.
- Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus. Nepal D, Gazeley D. Rheumatology (Oxford). 2023; 1;62(12):3804-3810. PMID: 37594751.
- Cytokines of the interleukin-6 family as emerging targets in inflammatory bowel disease. Garbers C, Lokau J. Expert Opin Ther Targets. 2024; 28(1-2):57-65. PMID: 38217849.
- Therapeutic uses of anti-interleukin-6 receptor antibody. Kang S et al., Int Immunol. 2015; 27(1):21-9. PMID: 25142313.
- The Role of IL-6 in Cancer Cell Invasiveness and Metastasis-Overview and Therapeutic Opportunities. Rašková M et al., Cells. 2022; 21;11(22):3698. PMID: 36429126.
- New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. Soler MF et al., J Immunother Cancer. 2023; 11(11):e007530. PMID: 37945321.
- IL-6 family cytokines as potential therapeutic strategies to treat metabolic diseases. Zhao J et al., Cytokine. 2021; 144:155549. PMID: 33962843